ArticleExperimental hematology & oncology2024

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.